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Walter Dembitsky, MDe‘‘Science without conscience is just ruin of the soul.’’
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From the early 1960s to the late 1990s, prosthetic heart
valve designs were improved through intense scientific
and clinical feedback. Mechanical heart valves, however,
still require warfarin-based anticoagulation, whereas long-
term durability remains a concern for bioprosthetic heart
valves, particularly in young adults and children. Thus the
current patient age guidelines for tissue versus mechanical
valve implants typically specify recipient ages older than
65 years for tissue valves and younger than 65 years for
mechanical valves.
Recent meta-analyses have shown that overall and event-
free survivals are similar for patients receiving mechanical
and biologic aortic valves.2,3 Selection of a valve device is
therefore based on a patient’s individual life expectancy,
ability to take anticoagulants, lifestyle, risk of bleeding, and
risk of reoperation. Operative mortality with conventional
surgery is low, even in octogenarians, and outcomes at 10
to 15 years and longer are satisfactory. A recent study of
1000 minimally invasive aortic valve replacements reported
on a large subgroup of elderly patients (>80 years) with an
operative mortality of 1.7%, a median hospital stay of 8
days, and an actuarial survival at 5 years of 84%.4
Commercially available valves are still based on concepts
largely unchanged from the 1970s and 1980s, with unmet
needs for more durable tissue valves and less thrombogenic
mechanical valves. These needs are urgent worldwide for pa-
tients younger than 65 years. In particular, the need is greatest
for juveniles and young adults in emerging countries and for
those requiring mitral valve replacement.5 Sadly, efforts to
achieve these high-priority goals seem largely to have ceased,
perhaps because of short-term financial considerations. This
situation is even more paradoxic now that advanced tech-
niques in fluid mechanics and molecular biology have iden-
tified, analyzed, and quantified causes of the thrombogenic
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valve opening and closure,6 nonphysiologic flow patterns,
vortex shedding, turbulence, abnormal flow (separation, stag-
nation, deceleration), energy loss, squeeze flow, microbubble
formation, solid emboli, and vapor cavitation, leading to
improved understanding of the link between traumatic forces
applied to blood elements, activation of the coagulation
cascade, and thromboembolic complications.7,8 Moreover,
it has been demonstrated that these functional liabilities can
be substantially reduced by improvements in valve design
and that a durable mechanical bioprosthesis not requiring
lifelong anticoagulation may be within reach.9,10
Instead, creative industrial energy has focused on catheter-
based valve delivery systems to implant devices currently
applicable to a small number of patients needing heart valve
replacement. The recent article by Mack,11 ‘‘Fool Me Once,
Shame on You; Fool Me Twice, Shame on Me! A Perspec-
tive on the Emerging World of Percutaneous Heart Valve
Therapy,’’ stimulated great interest in this subject.
There is no doubt that patients prefer less invasive proce-
dures and that a quest for better quality of life encourages
adoption of novel medical devices. Heart valve replacement
is a lifesaving procedure, however, and ‘‘surgery [is] an act
of authority on destiny,’’ as Rene´ Leriche put it.12 Prosthetic
heart valves must satisfy stringent technical requirements in
terms of safety and efficacy. Despite sophistication of deliv-
ery technology, it is quite challenging for catheter-based
valve therapy to conform to these requirements. At the
same time, it is important to overcome traditional medical
conservatism, as ironically described by C. Walton Lillehei
in his ‘‘seven steps of innovation.’’13 This ethical dilemma is
exacerbated when financial interests are involved. The abso-
lute criterion should therefore remain that the ultimate ben-
efit to the patient should be ‘‘here and now.’’ This leads to 3
crucial questions regarding applicability of transcatheter
valve therapy: (1) Can it be done? (2) Should it be done?
(3) How can it best be done? Of these 3 phases of techno-
logic evolution, transcatheter valves appear to be entering
phase 2, whereas traditional valve replacement has been in
phase 3 for many years.
Many patients with end-stage severe aortic stenosis are
not referred for surgery ostensibly because of advanced
age or major comorbidity. These patients are often left
with suboptimal strategies, such as balloon valvuloplasty.
To provide a better therapeutic alternative for these high-
risk patients with otherwise inoperable disease, percutane-
ous catheter-borne valve technology was introduced.
Although this option is rapidly developing, there are grow-
ing concerns about its extension to patients at lower risk. In andiovascular Surgery c Volume 139, Number 6 1371







Laging population, the number of patients with severe aortic
stenosis and reduced life expectancy is increasing. It has
been established that at least 1 of every 3 patients with severe
aortic stenosis has no symptoms. In the absence of symptoms,
the management of these patients is challenging. Frequently,
they are not offered surgery because mortality and the yearly
risks of prosthetic valve complications are greater than the
yearly risks of watchful waiting. Without aortic valve re-
placement, their survival is favorable: 99%, 98%, and
93% at 1, 2, and 5 years, respectively.14 Current practice
guidelines do not recommend surgery for these patients,
who may remain free of symptoms for many years. Approx-
imately a third of all patients with asymptomatic aortic steno-
sis show symptoms within 2 years, however, and the
prognosis may worsen significantly when symptoms de-
velop. It has been shown that only a minority of those with
potentially operable aortic valve stenosis undergo surgery.
As recent findings indicate, however, octogenarians may
live a lifespan comparable to that of the normal population af-
ter biologic aortic valve replacement.15
In Europe, 2 catheter-delivered valves have received CE
approval. In the United States the PARTNER-USA trial is
under way comparing outcomes for the Edwards-SAPIEN
transcatheter-delivered valve with those of standard aortic
valve replacement in high-risk patients and with those of
medical therapy, including aortic valvuloplasty, for patients
who are not surgical candidates. Study candidates must be
selected by 2 surgeons and 1 cardiologist. Interestingly,
patients who are offered surgery but decline are excluded.
A similar randomized study of the percutaneous CoreValve
delivery system is expected to begin soon. When mortality
and clinical outcomes of transcatheter valves compare favor-
ably with those of medical therapy alone or conventional
surgery, there is no doubt this specific growing population
of elderly, high-risk patients could be candidates for that
new therapeutic option.
Potential extension of transcatheter valve implantation to
lower risk patients with extended life expectancies along
a path similar to that observed with coronary stenting
deserves, however, the following observations. First, coro-
nary and vascular stents were initially introduced in the
clinical arena for the easiest cases. Subsequently, some inter-
ventionalists extended use to multivessel disease, bifurca-
tions, left main disease, renal and carotid arteries, and so
on. Reports of restenosed lesions encouraged adoption of
new stent models before evidence of long-term efficacy.
This ‘‘earn-while-you-learn’’ aberration eroded traditional
evidence-based decision making. Currently, transcatheter
valve replacement is only proposed for high-risk patients
otherwise restricted to medical therapy alone.
Second, coronary stents and prosthetic heart valves are
passive devices. Unlike stents, however, prosthetic heart
valves must withstand wide ranging dynamic stress and cy-
clic loading for many years. Valve substitutes must also1372 The Journal of Thoracic and Cardiovascular Surcomply with the stringent requirements of the international
norm (ISO 5840) that mandates a systematic risk analysis
and risk reduction to the very minimum.
To our knowledge, this regulatory issue has not as yet
been resolved for transcatheter-inserted valves. Recent US
Food and Drug Administration Advisory Panel comments
are pertinent. ‘‘In contrast, the developing field of percutane-
ous heart valve insertion demands innovative trial designs to
address difficult new concerns. These concerns include de-
fining target populations; establishing the correct risk/bene-
fit ratio based on a new balance between safety and
effectiveness perceived for the reduction in surgical risk;
and choice of appropriate endpoints for assessment. Al-
though innovative trial design may be necessary in certain
cases of new technology, the most appropriate study design
remains a randomized controlled trial as the gold
standard.’’16
There is a tacit assumption that durability for catheter-
delivered tissue valves will be similar to that of current,
conventional tissue valves, but this has yet to be determined.
For the standard stented porcine and pericardial valve, dura-
bility appears to be between 10 and 20 years. The freedoms
from structural valve failure are 70% to 90% at 10 years and
50% to 80% at 15 years, but substantially less in younger
patients.17
Bicuspid aortic valve malformations typically calcify
earlier and more intensively than do archetypal aortic valves,
are often associated with ascending aortic wall pathology,
and are considered a contraindication for percutaneous or
transapical replacement. It is estimated these valves repre-
sent more than 50% of all aortic stenosis cases in industrial-
ized societies,18 and operative therapy will clearly remain
the treatment of choice for the foreseeable future.
The risk–benefit ratio of transcatheter valves for high-risk
patients (Society of Thoracic Surgeons score>10%) with
less than 5 years of life expectancy could be acceptable.19
For this population of patients, current studies20 suggest
that mortality and short-term morbidity could be competitive
with conventional surgery, although the exact relevance of
these studies remains to be established.
Finally, extension of transcatheter aortic valve indications
to younger patients who are candidates for mechanical valve
replacement would increase the potential for a ‘‘valve-in-
valve’’ replacement or other experimental procedures. The
demonstration of safety and efficacy of these procedures
may require substantial additional time and very likely can-
not be repeated more than once. It should be noted that even
in the elderly population, conventional reoperative valvular
surgery has been performed with less than 11%mortality.21
For catheter-delivered valves, transfemoral and transapical
approaches both require rapid ventricular pacing, critical
anesthetic management of hypotension and arrhythmias dur-
ing beating-heart valve implantation, and transesophageal
echocardiography. Although transcatheter aortic valvegery c June 2010







Linsertion may become a valuable therapeutic option for high-
risk patients with severe aortic stenosis and short life expec-
tancy, it will still carry considerable risk.22 In the best case,
wider application of transcatheter aortic valve implantation
will require much more time and additional study, including
head-to-head comparisons with conventional valve replace-
ment and apicoaortic bypass in diverse risk populations.
Those familiar with heart valve history will remember that
many new designs had encouraging early performance,
leading to erroneous projections of durability and patient
benefits. In fact, only a few valves have withstood the test
of time, and patients unfortunate enough to have received
less safe and effective prostheses paid the price in mortality,
morbidity, and additional surgery. It is also worth remem-
bering that failed valve designs far outnumber those that
proved successful.
In response to approvals for catheter-delivered valve
devices and other concerns, health authorities in Belgium
have recently expressed specific recommendations: ‘‘Today,
reimbursement of percutaneous aortic valves cannot be de-
fended because of the many unsolved questions regarding
safety of patients and the lack of a target population.
Published data are not convincing regarding the fact that
the risk associated with the procedure of percutaneous valve
implant could be less than the regular surgical procedure.
The high mortality at 6 months questions the safety of this
procedure. The medical community should be well informed
on the fact that the CE mark does not indicate a device is safe
for clinical use.’’23
Whereas large financial investments presently involved in
transcatheter valve delivery technologies are devoted to the
elderly population, little recently has been done for the much
larger population of younger patients and children world-
wide who need a durable heart valve substitute that performs
safely without warfarin anticoagulation.24 It is probable that
catheter-based valve technology will result in an attractive
option for a specific segment of the valve replacement pop-
ulation. We believe, however, that it is also important for in-
dustry to focus on development of improved devices for the
great majority of patients needing valve replacement. As we
have all known, it is difficult to make something simple.
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